Pfizer Chairman and CEO Dr. Albert Bourla to Receive the 2024 AACR Outstanding Achievement Award for Service to Cancer Science and Medicine
The American Association for Cancer Research (AACR) will honor Pfizer Inc., as well as Pfizer’s chairman and chief executive officer, Albert Bourla, PhD, with the 2024 AACR Outstanding Achievement Award for Service to Cancer Science and Medicine during the AACR Annual Meeting 2024, to be held April 5-10 in San Diego, California. Bourla will accept the award and give remarks during the meeting’s Opening Ceremony, which begins Sunday, April 7 at 8 a.m. PT.
Pfizer, along with Bourla as its chairman and CEO, is being honored for its long-standing and impressive work in oncology, its deep-rooted commitment to scientific innovation in the development of novel cancer therapeutics, and its steadfast and enduring commitment to the AACR.
In December 2023, Pfizer announced that it had chosen to donate the rights of its royalties from the sale of Bavencio® (avelumab) in the United States to the AACR, as an acknowledgment of the AACR’s unwavering dedication to sustained innovation in cancer research and treatment. This generous donation will support the AACR’s mission to accelerate the prevention and cure of all cancers through cutting-edge cancer research for the benefit of patients around the world.
In addition to this transformative donation, Pfizer has partnered with the AACR for many years to support impactful research and further the careers of eminent cancer scientists and physicians. The company has participated in, and made possible, numerous AACR scientific meetings and think tanks where leaders from the national and international cancer research community have disseminated their novel findings. By facilitating this sharing of information, Pfizer has played a crucial role in fostering collaboration and collective progress against cancer, effectively revolutionizing cancer research and patient care.
“On behalf of the AACR Board of Directors, I have the great honor to recognize Pfizer, and Dr. Bourla as its chairman and CEO, with this richly deserved award,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “Pfizer’s sustained and ongoing contributions to progress against cancer are an inspiration to the entire cancer research community. We look forward to celebrating Dr. Bourla and his distinguished colleagues at Pfizer for their stalwart commitment to the cause and for their many remarkable scientific achievements.”
“Pfizer is committed to the fight against cancer and will continue to collaborate across the healthcare ecosystem so that we can deliver the next generation of cancer care,” said Bourla. “It is an honor to be recognized by the AACR for the work Pfizer colleagues do every day to bring new innovations for patients everywhere.”
Journalists can request virtual or in-person media registration for the AACR Annual Meeting, including the Opening Ceremony.
Press Registration Form